Insight, China's Pharmaceutical Industry

Company

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

The Global Medical Device Training, Exhibition, Trading and Innovation Center was officially inaugurated this week...

Company Drug

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a...

Company Drug

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Fineline Cube May 27, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics...

Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026

Insilico Medicine (HKG: 3696) and Human Life Foundation Models (HLFM), a newly established spin-off from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Fineline Cube May 27, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China...

Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026

Eli Lilly and Company (NYSE: LLY) announced strategic agreements to acquire Curevo Inc., LimmaTech Biologics...

Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026

Shanghai Simpletouch Robot Co., Ltd. has filed its prospectus with the Hong Kong Stock Exchange...

Company Deals

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Fineline Cube May 26, 2026

Qingfeng Pharmaceutical Group Co., Ltd. announced a licensing agreement with Merz Therapeutics GmbH, a German...

Company Deals

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Fineline Cube May 26, 2026

Peak Pharmaceutical Co., Ltd. announced a strategic partnership with SPH Kyuan Trade, a core subsidiary...

Others

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

Fineline Cube May 26, 2026

Hotgen Biotech Co., Ltd. (SHA: 688068) announced that the National Medical Products Administration (NMPA) has...

Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026

China’s National Medical Products Administration (NMPA) has released the “Compliance Guidelines for Online Retail of...

Company Drug

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

Fineline Cube May 26, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical...

Others

CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage

Fineline Cube May 26, 2026

CanSino Biologics Inc. (HKG: 6185) announced the initiation of its Phase I/II clinical study for...

Company Drug

China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease

Fineline Cube May 26, 2026

China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization...

Company Medical Device

MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System – Advanced Solution for Complex Neurovascular Lesions

Fineline Cube May 26, 2026

MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food...

Company Drug

Eli Lilly Reports Positive Phase 1b Results for VERVE-102 Base Editing Therapy with Sustained LDL-C Reductions Up to 18 Months

Fineline Cube May 26, 2026

Eli Lilly and Company (NYSE: LLY) announced positive interim results from the Phase 1b Heart-2...

Company Deals

Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare

Fineline Cube May 26, 2026

Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced an expanded strategic...

Company Deals

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Fineline Cube May 26, 2026

Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow...

Company Drug

Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer

Fineline Cube May 26, 2026

Pierre Fabre Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human...

Company Drug

OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors

Fineline Cube May 26, 2026

OTR Therapeutics announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate...

Insight, China's Pharmaceutical Industry

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Boston Scientific, Danaher, and Siemens Healthineers Launch A3 International Medical Technology Innovation Center at Shanghai Eastern Hub

Shanghai Henlius Biotech Initiates Phase II/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC

Hengrui Pharmaceuticals and Kailera Therapeutics Report Strong Phase III Results for Oral GLP-1 Agonist HRS-7535 in Type 2 Diabetes

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Shanghai Henlius Biotech Doses First Patient in China for Global Phase I Study of Daratumumab Biosimilar HLX15-SC in Multiple Myeloma

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Qingfeng Pharmaceutical Secures Greater China Rights to Merz’s Inbrija Levodopa Inhalation Powder for Parkinson’s Disease OFF Episodes

Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China

Hotgen Biotech Secures NMPA Clinical Filing Acceptance for SGC001 Monoclonal Antibody in Severe Acute Pancreatitis

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease

CanSino Biologics Initiates Phase I/II Trial for PCV24 Pneumococcal Conjugate Vaccine with Enhanced Serotype Coverage

China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease

MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System – Advanced Solution for Complex Neurovascular Lesions

Eli Lilly Reports Positive Phase 1b Results for VERVE-102 Base Editing Therapy with Sustained LDL-C Reductions Up to 18 Months

Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare

ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma

Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer

OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors

You Missed

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody